Siegfried

Executive Summary

Siegfried is a premier global CDMO with over 150 years of experience, offering integrated services from drug substance to drug product. Operating 13 facilities across three continents, the company supports over 500 clients from early-phase development to commercial manufacturing. Its long-standing track record, regulatory expertise, and broad capabilities in small molecules, drug delivery, and biologics position it well to benefit from the growing outsourcing trend in pharma. Siegfried's consistent investment in capacity expansion and technology upgrades supports its competitive edge, though its private status limits public financial visibility. The company is expected to maintain steady growth driven by sustained demand for CDMO services, with potential upside from new long-term contracts and expansions in high-potency and biologic manufacturing.

Upcoming Catalysts (preview)

• Q3 2026Completion of Capacity Expansion at Key European Sites80% success
• TBDNew Long-Term Manufacturing Agreement with Top 20 Pharma60% success
• Q3 2026Regulatory Approval for New High-Potency API Facility70% success